P Pu ur rp po os se e: : The present study was undertaken following the observation of a marked decrease in myocardial contractility after ropivacaine in a patient on amiodarone, in order to investigate the cardiovascular effects of combining ropivacaine with anti-arrhythmic drugs (AARD).
M Me et th ho od ds s: : Anesthetized domestic pigs were treated with disopyramide, flecainide, atenolol, amiodarone, diltiazem or nicardipine at a dose leading to blood levels obtained in treated patients, then received 1 mg·kg -1 ropivacaine. Blood pressure (BP), left venticular (LV) dP/dt max, sinus heart rate, and intraventricular conduction time were measured before and following the administration of AARD, and following ropivacaine at different time points.
R Re es su ul lt ts s: : All tested AARD induced the expected hemodynamic and electrophysiologic effects. Following ropivacaine, a 20 to 35% decrease in LV dP/dt max of prolonged duration was observed with amiodarone only. A brief 10 to 20% decrease in mean BP was observed in all animals, except those treated with nicardipine who sustained an important and prolonged decrease in BP. All other variables were not significantly affected.
D Di is sc cu us ss si io on n: : The combination of ropivacaine with AARD was always associated with a slight drop in LV dP/dt max. The effect on mean BP was slight, except with nicardipine. Clinicians should be aware of the interactions of ropivacaine with AARD, especially amiodarone and nicardipine. OPIVACAINE is widely used because its reduced diffusion and vasoconstricting properties result in lower blood levels and less toxic effects than with other local anesthetics, 1 particularly bupivacaine. 2 Following the observation of unexpected and severely impaired cardiac contractility evidenced by transthoracic echocardiography after local anesthesia with ropivacaine in one of our patients treated with amiodarone, the question arose of possible adverse interactions between ropivacaine and anti-arrhythmic drugs (AARD). This study was undertaken to investigate, in pigs, the hemodynamic and cardiac electrophysiological effects of combinations of ropivacaine with several AARD. ). The dose of ropivacaine was 1 mg·kg -1 . A preliminary study showed that the measured blood levels (1 µg·kg ) were close to those seen in man after loco-regional anesthesia. 3 All end-points were recorded twice at five-minute intervals prior, then one and two minutes after each AARD administration (one minute infusion), and finally one, two, five, ten, 15, 30 and 60 min after cessation of ropivacaine administration (one minute infusion started two minutes after the end of AARD administration).
Objectif
ANOVA for repeated measurements with Greenhouse-Geisser correction was used to evidence drug and time effects. Paired t tests corrected by Bonferroni for multiple samples were used to compare means of measured end-points in each group at different time points. R Re es su ul lt ts s No changes in mBP or LVdP/dt max were observed in animals receiving ropivacaine alone ( Figure 1 ). As expected, mBP and LVdP/dt decreased after the injection of AARD. After the injection of ropivacaine, a 20 to 35% decrease in LV dP/dt max was observed in all groups. The decrease was prolonged only in animals pretreated with amiodarone ( Figure 2) . A brief 10 to 20% decrease in BP was observed, except in ani- Table I (available as "additional material" at www.cja-jca.org). Table II (available as "additional material" at www.cja-jca.org). mals pretreated with nicardipine where the decrease in BP was important ans dustained ( Figure 3) . Detailed hemodynamic and electophysiologic results are available as "additional material" at www.cja-jca.org (Tables I and II). D Di is sc cu us ss si io on n In this study, all AARD tested induced the expected hemodynamic and electrophysiologic effects. The Na + -blocking drugs disopyramide and flecainide reduce intraventricular conduction by depressing the fast sodium channel. 4 Both drugs depress cardiac contractility (decreased LV dP/dt max) by altering the Na + /Ca ++ exchange system that plays a key role in myocyte calcium concentrations 5 resulting in reduced calcium concentrations in the sarcoplasmic reticulum. The reduction in LV dP/dt max is greater with disopyramide than with flecainide 6 because disopyramide markedly increases vascular resistances. Atenolol induces bradycardia, decreases BP and LV dP/dt max via its ß-blocking effects, but produces no changes in the QT interval or QRS complexes. The amiodaronerelated decrease in LV dP/dt max is mainly due to decreased calcium levels in the sarcoplasmic reticulum and not to decreased calcium influx. Amiodarone reduces HR and increases the QTc interval. As regards calcium inhibitors, Dong et al. 7 found that the depression in cardiac contractility is more marked with diltiazem than with nicardipine. Calcium inhibitors induce bradycardia without changes in the QT interval and QRS complexes.
The cardiotoxicity of local anesthetics is linked to their blood distribution, myocardial tissue binding, Na + -blocking capacities and effects on Na + /Ca ++ exchanges. The risk of ventricular conduction contractility disorders is greater with high Na + -blocking potency (bupivacaine) and is thus lower with ropivacaine. The risk of ventricular fibrillation and other major cardiac disorders is less following ropivacaine than bupivacaine. 8 Following ropivacaine, all electrophysiological endpoints remained at the level seen after the administration of each AARD. This can be explained by the relatively low Na + -blocking potency of ropivacaine. 9 In contrast, the combination of ropivacaine with several AARD resulted in a markedly reduced LV dP/dt max. The negative inotropic effects of ropivacaine, although mild, 1 are additive to those of AARD. Depending on the AARD, three patterns of reduction in LV dP/dt max were seen: marked and prolonged (> 30 min) with amiodarone; transient (< ten minutes) but significant with disopyramide, flecainide, atenolol and nicardipine; slight and very transient with diltiazem. With diltiazem, LV dP/dt max increased ten minutes after ropivacaine. The mechanism of the incremental reduction in LV dP/dt max by ropivacaine after the administration of AARD could involve an additive inhibition of Ca ++ influx with class IV AARDS, and the Na + /Ca 2+ exchange system with the Na + blocking disopyramide and flecainide. An inhibition of 3',5'-AMPc production by ropivacaine is another possibility. 10 This inhibition could be mediated by receptor-operated channels resulting in decreased intracellular calcium concentrations resulting in reduced cardiac contractility. The blockade of Ca ++ influx through voltage-dependent calcium channels by calcium inhibitors inhibits the signal required by the sarcoplasmic reticulum to release stored Ca ++ . The lack of effects of the ropivacaine-diltiazem combination on cardiac contractility could be due to improved hemodynamic conditions as suggested by the reduced bradycardia and increased BP.
In conclusion, this study in pigs demonstrates that ropivacaine combined to various AARD induces no significant electrophysiological changes. In most cases, alterations in cardiac contractility were mild and transient, except with amiodarone (decreased LV dP/dt max) and nicardipine (decreased BP). Careful per-and postsurgical follow-up of patients is recommended in patients treated with either amiodarone or nicardipine following ropivacaine administration. Table II (available as "additional material" at www.cja-jca.org).
